MercadoLibre Expands Pharmacy Push to Chile After Brazil Launch

What happened

MercadoLibre has discussed with Chilean authorities a proposal to operate as a pharmacy, requiring regulatory changes, following a similar launch in Brazil. This move signals the company's ambition to enter the healthcare vertical, leveraging its logistics and fintech platform. However, the near-term financial impact is minimal given the heavy ongoing investments in logistics and credit expansion. The company's Q1'26 results showed operating income declining 20% y/y and credit provisioning surging to $1.2B, underscoring the margin pressure. Thus, while new verticals are promising, the core thesis hinges on logistics efficiency and credit cost management in the next 6-12 months.

Implication

The move to add pharmacy services in Chile and Brazil demonstrates MercadoLibre's ability to extend its ecosystem into new high-frequency categories, potentially driving higher GMV and user engagement over time. However, the regulatory hurdles and investment required mean this initiative will not contribute meaningfully to earnings in the next 12-18 months. Investors should focus on the core thesis: logistics unit-cost deflation and credit cost normalization. The pharmacy expansion is incremental and does not change the WAIT rating at current valuation of ~43x P/E. A better entry point would be below $1,500 or after a quarter of margin stabilization and lower provisioning.

Thesis delta

The pharmacy push adds a new growth vector but does not shift the near-term investment thesis. The company's decision to enter a regulated sector introduces additional execution and regulatory risk, but it also highlights the platform's optionality. The core focus remains on logistics scale and credit quality; the pharmacy initiative is unlikely to move the needle in the next 6-12 months.